The Development and Use of Scalable Systems for Studying Aberrant Splicing in SF3B1-Mutant CLL

Area of Science:

• Molecular Biology
• Genetics
• Oncology

Background:

• Chronic lymphocytic leukemia (CLL) exhibits recurrent mutations in SF3B1, a key splicing factor.
• These SF3B1 mutations, found in 5-10% of newly diagnosed CLL, affect splicing by promoting the use of cryptic 3' splice sites (3SS).
• SF3B1 mutations are not exclusive to CLL and are observed in other clonal disorders.

Purpose of the Study:

• To investigate the functional consequences of SF3B1 mutations in CLL.
• To present and validate methodologies for studying SF3B1 mutations in CLL.
• To enable detailed analysis of transcriptomic changes associated with SF3B1 mutations.

Main Methods:

• Development of scalable isogenic cell line models for SF3B1-mutant CLL.
• Bioinformatic analysis of RNA-sequencing (RNA-Seq) datasets to identify splicing aberrations.
• Utilizing advances in genome editing and next-generation sequencing (NGS) for precise molecular analysis.

Main Results:

• SF3B1-mutant CLL cells demonstrate aberrant splicing patterns, specifically the utilization of novel 3' splice sites.
• Isogenic models and RNA-Seq analysis provide a robust framework for studying the impact of SF3B1 mutations.
• Established methods allow for detailed characterization of transcriptome alterations in SF3B1-mutant cells.

Conclusions:

• SF3B1 mutations represent a significant molecular feature in a subset of CLL patients.
• The developed methodologies facilitate the study of splicing factor mutations and their impact on gene expression in CLL.
• Further research into SF3B1-mutant CLL may reveal new therapeutic targets and improve patient stratification.